Ocular changes in patients on Topiramate therapy: a hospital-based comparative study
Abstract
BACKGROUND: To evaluate the effect of newly administered Topiramate therapy on various ophthalmological parameters. METHODS: This was a hospital-based, prospective, non-randomized, longitudinal, comparative study conducted in the Department of Ophthalmology at a tertiary care hospital from August 2024 to March 2025. Patients aged between 18 and 40 years, and newly initiated on Topiramate therapy by the department of Neurology, were recruited in the study and constituted the study group. Age- and gender-matched healthy individuals constituted the control group. A comprehensive ophthalmic evaluation was done in every case. Ocular parameters studied were intraocular pressure (IOP), central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT), and peripapillary retinal nerve fiber layer (RNFL) thickness. Assessment was performed at baseline and at 15 days, 1 month, and 3 months following Topiramate therapy. RESULTS: A total of 160 eyes of 80 patients (40 patients newly initiated on Topiramate therapy and 40 healthy controls) were analyzed in the study. The mean age was 30.27 ± 4.83 years and 30.7 ± 4.6 years, respectively, in both groups. Significant increases were observed in IOP (from 13.46 ± 1.71 mm Hg to 18.18 ± 2.48 mm Hg, P < 0.001), CCT (from 516.76 ± 34.58 μm to 524.38 ± 36.04 μm, P < 0.001), LT (from 3.81 ± 0.33 mm to 3.85 ± 0.33 mm, P < 0.001), and peripapillary RNFL thickness (P < 0.001 in all quadrants). ACD showed a significant reduction over…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 80 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.